Type 1 Diabetes

Pivotal Phase IIb Clinical Trial Under Way For Therapeutic Vaccine

Published in Vaccine Weekly, January 23rd, 2002

Neurocrine Biosciences, Inc., (NBIX) and Taisho Pharmaceutical Co., Ltd., have initiated the first pivotal Phase IIb clinical trial of NBI-6024, a therapeutic vaccine, in approximately 400 adult and adolescent patients with new onset type 1 diabetes.

The initiation of this trial with NBI-6024 is the first of two studies planned. A second Phase IIb trial is planned to begin during 2002. Successful completion of these two Phase IIb trials may support the marketing of NBI-6024 for type 1 diabetes. Neurocrine will receive an undisclosed milestone payment from Taisho as a result of the initiation of this Phase IIb clinical trial. The two companies entered into a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-01-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry